A notable advancement in glucose care is emerging with the release of tirzepatide at a dosage of 45mg. This updated version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and delivers a https://bookmarkshq.com/story23144898/revolutionary-approach-tirzepatide-45mg-for-glucose-control